These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 10895211)

  • 41. Utility of free prostate specific antigen serum level and its related parameters in the diagnosis of prostate cancer.
    Haroun AA; Hadidy AS; Awwad ZM; Nimri CF; Mahafza WS; Tarawneh ES
    Saudi J Kidney Dis Transpl; 2011 Mar; 22(2):291-7. PubMed ID: 21422628
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Incidence of prostatic cancer in symptomatic patients with non-suspicious rectal palpation and PSA levels greater than 10 ng/ml].
    Herranz Amo F; Verdú Tartajo F; Díez Cordero JM; Bueno Chomón G; Leal Hernández F; Bielsa Carrillo A; García Burgos J
    Actas Urol Esp; 1999 Apr; 23(4):316-22. PubMed ID: 10394651
    [TBL] [Abstract][Full Text] [Related]  

  • 44. T1c prostate cancer detection rate and pathologic characteristics: comparison between patients with serum prostate-specific antigen range of 3.0 to 4.0 ng/mL and 4.1 to 10.0 ng/mL in Korean population.
    Park HK; Hong SK; Byun SS; Lee SE
    Urology; 2006 Jul; 68(1):85-8. PubMed ID: 16806412
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of transperineal six-core prostate biopsy in patients with prostate-specific antigen level greater than 10 ng/mL and abnormal digital rectal examination findings.
    Luciani LG; De Giorgi G; Valotto C; Zanin M; Bierti S; Zattoni F
    Urology; 2006 Mar; 67(3):555-8. PubMed ID: 16527579
    [TBL] [Abstract][Full Text] [Related]  

  • 46. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
    Roobol MJ; van der Cruijsen IW; Schröder FH
    Urology; 2004 May; 63(5):892-7; discussion 897-9. PubMed ID: 15134973
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
    Bangma CH; Rietbergen JB; Kranse R; Blijenberg BG; Petterson K; Schröder FH
    J Urol; 1997 Jun; 157(6):2191-6. PubMed ID: 9146612
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Diagnosis of cancer of the prostate by determining the blood levels of specific prostatic antigen, rectal examination, and transrectal echography].
    Isa Kroon WA; Robles JE; de Castro F; Rosell D; Abad JI; Zudaire JJ; Berián JM
    Actas Urol Esp; 1993 Jun; 17(6):341-5; discussion 345-6. PubMed ID: 7690176
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The detection rate of prostate cancer in different prostate-specific antigen (PSA) levels in Chinese men].
    Li M; Na YQ
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(1):16-8. PubMed ID: 18346372
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A multicenter study on the detection of prostate cancer by digital rectal examination and prostate-specific antigen in men with or without urinary symptoms. Cooperative Group for Diagnosis of Prostate Cancer.
    Eur Urol; 1997; 32(2):133-9. PubMed ID: 9286642
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of prostate-specific antigen density in predicting prostate cancer when serum prostate-specific antigen levels are less than 10 ng/ml.
    Akdas A; Tarcan T; Türkeri L; Cevik I; Biren T; Ilker Y
    Eur Urol; 1996; 29(2):189-92. PubMed ID: 8647145
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment.
    Aus G
    Scand J Urol Nephrol Suppl; 1994; 167():1-41. PubMed ID: 7542397
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PSA density and prostate cancer detection.
    Saema A; Kochakarn W; Lertsithichai P
    J Med Assoc Thai; 2012 May; 95(5):661-6. PubMed ID: 22994025
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of prostate-specific antigen (PSA) and PSA density in the detection of stage T1 carcinoma of the prostate.
    Presti JC; Carroll PR
    Semin Urol Oncol; 1996 Aug; 14(3):134-8. PubMed ID: 8865474
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The current role of prostatic acid phosphatase and prostate-specific antigen in the management of prostate cancer.
    Shetty SD; Cerny JC
    Henry Ford Hosp Med J; 1992; 40(1-2):93-8. PubMed ID: 1385363
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Significance of serum free prostate specific antigen in the screening of prostate cancer.
    Higashihara E; Nutahara K; Kojima M; Okegawa T; Miura I; Miyata A; Kato M; Sugisaki H; Tomaru T
    J Urol; 1996 Dec; 156(6):1964-8. PubMed ID: 8911366
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clinical significance of prostate specific antigen (PSA) and PSA density in the detection of T1a and T1b prostate cancer].
    Meguro N; Maeda O; Saiki S; Kinouchi T; Kuroda M; Usami M; Kotake T
    Hinyokika Kiyo; 1998 Sep; 44(9):639-43. PubMed ID: 9805668
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations.
    Gohji K; Nomi M; Egawa S; Morisue K; Takenaka A; Okamoto M; Ohori M; Fujii A
    Cancer; 1997 May; 79(10):1969-76. PubMed ID: 9149025
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density.
    Bangma CH; Kranse R; Blijenberg BG; Schröder FH
    Urology; 1995 Dec; 46(6):779-84. PubMed ID: 7502415
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk.
    Morote J; Planas J; Ramirez C; Gómez E; Raventós CX; Placer J; Catalán R; de Torres IM
    BJU Int; 2010 Feb; 105(4):481-4. PubMed ID: 19681902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.